Inventor
MARTINELL PEDEMONTE MARC
ES17 patents
⚠️ This page may combine multiple inventors who share the name “MARTINELL PEDEMONTE MARC”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ORYZON GENOMICS SA
10 patentsUS9670136B2Jun 6, 2017
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
ORYZON GENOMICS SA8 citations83
US9708309B2Jul 18, 2017
Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
ORYZON GENOMICS SA7 citations82
US9676701B2Jun 13, 2017
Cyclopropylamine derivatives useful as LSD1 inhibitors
ORYZON GENOMICS SA7 citations82
US9487512B2Nov 8, 2016
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
ORYZON GENOMICS SA8 citations82
US9469597B2Oct 18, 2016
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
ORYZON GENOMICS SA8 citations81
US10329256B2Jun 25, 2019
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
ORYZON GENOMICS SA1 citations72
US10214477B2Feb 26, 2019
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
ORYZON GENOMICS SA1 citations72
US9944601B2Apr 17, 2018
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
ORYZON GENOMICS SA4 citations72
US10233178B2Mar 19, 2019
Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use
ORYZON GENOMICS SA1 citations71
US9908859B2Mar 6, 2018
Lysine demethylase inhibitors for myeloproliferative disorders
ORYZON GENOMICS SA6 citations68
MINORYX THERAPEUTICS S L
5 patentsUS9782395B2Oct 10, 2017
2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
MINORYX THERAPEUTICS S L13 citations76
US10179126B2Jan 15, 2019
2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
MINORYX THERAPEUTICS S L2 citations67
US11938122B2Mar 26, 2024
5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
MINORYX THERAPEUTICS S L0 citations59
US11957670B2Apr 16, 2024
5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
MINORYX THERAPEUTICS S L0 citations53
US11440898B2Sep 13, 2022
Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase
MINORYX THERAPEUTICS S L0 citations42